Shopping Cart 0
Cart Subtotal
USD 0

Xintela AB (XINT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company's technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also provides analytical test such as XACT (Xintela Assay for Cell Therapy), used for quality assurance of methods and cells. Xintela's analytical test finds application in research and development activities for stem cell products. It develops therapeutic antibodies, which bind to cancer cells. The company conducts its research in the fields of regenerative medicine and cancer with significance on cartilage damage such as osteoarthritis and brain cancer. Xintela is headquartered in Lund, Sweden.

Xintela AB (XINT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Xintela AB, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Xintela Raises USD 0.9 Million In Venture Financing 10

Partnerships 11

CO.DON to Form Joint Venture with Xintela 11

Xintela Enters into Collaboration Agreement with CellSeed 12

Xintela to Enter into Agreement with Co.don 13

Licensing Agreements 14

Xintela Licenses Human Antibody Technology for Cancer Therapy 14

Equity Offering 15

Xintela Raises USD1.1 Million in Private Placement of Shares 15

Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16

Xintela Completes Underwriter's Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17

Xintela AB-Key Competitors 18

Xintela AB-Key Employees 19

Xintela AB-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Strategy And Business Planning 21

Aug 29, 2018: Xintela to spin out oncology business 21

Sep 11, 2017: Xintela building own GMP-facility for stem cell production 22

Corporate Communications 23

Aug 29, 2018: Xintela appoints Sven Kili as Chief Medical Officer 23

Oct 17, 2017: Keld Sondergaard leaves Xintela's Board of Directors 24

Product News 25

Dec 29, 2017: Xintela licenses human antibody technology for cancer therapy 25

Apr 17, 2018: Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio 26

Other Significant Developments 27

Aug 21, 2018: Xintela: Significant progress in development programs 27

Apr 26, 2018: Xintela's GMP facility is completed and being prepared for production and clinical trials 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Xintela AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xintela AB, Deals By Therapy Area, 2012 to YTD 2018 8

Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Xintela Raises USD 0.9 Million In Venture Financing 10

CO.DON to Form Joint Venture with Xintela 11

Xintela Enters into Collaboration Agreement with CellSeed 12

Xintela to Enter into Agreement with Co.don 13

Xintela Licenses Human Antibody Technology for Cancer Therapy 14

Xintela Raises USD1.1 Million in Private Placement of Shares 15

Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16

Xintela Completes Underwriter's Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17

Xintela AB, Key Competitors 18

Xintela AB, Key Employees 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Xintela AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company's technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also provides analytical test such as XACT (Xintela Assay for Cell Therapy), used for quality assurance of methods and cells. Xintela's analytical test finds application in research and development activities for stem cell products. It develops therapeutic antibodies, which bind to cancer cells. The company conducts its research in the fields of regenerative medicine and cancer with significance on cartilage damage such as osteoarthritis and brain cancer. Xintela is headquartered in Lund, Sweden.

Xintela AB (XINT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Xintela AB, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Xintela Raises USD 0.9 Million In Venture Financing 10

Partnerships 11

CO.DON to Form Joint Venture with Xintela 11

Xintela Enters into Collaboration Agreement with CellSeed 12

Xintela to Enter into Agreement with Co.don 13

Licensing Agreements 14

Xintela Licenses Human Antibody Technology for Cancer Therapy 14

Equity Offering 15

Xintela Raises USD1.1 Million in Private Placement of Shares 15

Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16

Xintela Completes Underwriter's Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17

Xintela AB-Key Competitors 18

Xintela AB-Key Employees 19

Xintela AB-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Strategy And Business Planning 21

Aug 29, 2018: Xintela to spin out oncology business 21

Sep 11, 2017: Xintela building own GMP-facility for stem cell production 22

Corporate Communications 23

Aug 29, 2018: Xintela appoints Sven Kili as Chief Medical Officer 23

Oct 17, 2017: Keld Sondergaard leaves Xintela's Board of Directors 24

Product News 25

Dec 29, 2017: Xintela licenses human antibody technology for cancer therapy 25

Apr 17, 2018: Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio 26

Other Significant Developments 27

Aug 21, 2018: Xintela: Significant progress in development programs 27

Apr 26, 2018: Xintela's GMP facility is completed and being prepared for production and clinical trials 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Xintela AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xintela AB, Deals By Therapy Area, 2012 to YTD 2018 8

Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Xintela Raises USD 0.9 Million In Venture Financing 10

CO.DON to Form Joint Venture with Xintela 11

Xintela Enters into Collaboration Agreement with CellSeed 12

Xintela to Enter into Agreement with Co.don 13

Xintela Licenses Human Antibody Technology for Cancer Therapy 14

Xintela Raises USD1.1 Million in Private Placement of Shares 15

Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16

Xintela Completes Underwriter's Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17

Xintela AB, Key Competitors 18

Xintela AB, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Xintela AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.